FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to the isolated nucleic acid molecule encoding the chimeric antigen receptor (CAR), as well as to the vector and cell containing it. Also disclosed is a dedicated chimeric antigen receptor (CAR) polypeptide that binds to BCMA, as well as a dedicated binding domain against B-cell maturation antigen (BCMA) that binds to BCMA. The invention also relates to a method for producing an immune effector cell, as well as a method for producing a population of RNA-engineered cells, involving the use of the above-mentioned nucleic acid molecule.
EFFECT: invention is effective for treatment of a mammal with a disease associated with BCMA expression, as well as for achieving antitumor immunity in a mammal with a disease associated with BCMA expression.
53 cl, 47 dwg, 27 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| CHIMERIC ANTIGEN RECEPTORS M971 | 2018 |
|
RU2770411C1 |
| TREATMENT OF MALIGNANT TUMOR USING ANTI-CD19 ANTIGEN CHIMERIC RECEPTOR | 2015 |
|
RU2815417C2 |
